You have 9 free searches left this month | for more free features.

pemetrexed

Showing 26 - 50 of 527

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Lung Cancer Trial in Nashville (Pemetrexed, Gemcitabine)

Completed
  • Lung Cancer
  • Nashville, Tennessee
    Tennessee Oncology
Feb 21, 2022

Non Small Cell Lung Cancer Trial in Tianjin (Osimertinib, Bevacizumab Biosimilar IBI305, Carboplatin)

Recruiting
  • Non Small Cell Lung Cancer
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute and Hospital
Aug 18, 2022

NSCLC Metastatic Trial in Salt Lake City (Durvalumab, Pemetrexed, Carboplatin)

Recruiting
  • Non-Small Cell Lung Cancer Metastatic
  • Salt Lake City, Utah
    Huntsman Cancer Institute at University of Utah
Mar 1, 2022

NSCLC Trial in Tianjin (Tislelizumab, Pemetrexed, Bevacizumab)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute and Hospital
Jul 11, 2022

Non Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer, Urothelial Carcinoma Trial in Augusta (Cabozantinib,

Recruiting
  • Non Small Cell Lung Cancer
  • +3 more
  • Augusta, Georgia
    Augusta University Georgia Cancer Center
Mar 6, 2022

MPM Trial in Changchun (PM8002, Pemetrexed, Cisplatin)

Recruiting
  • MPM
  • Changchun, China
    Jilin Provincial Tumor Hospital
Jun 25, 2023

Metastatic Non-squamous Non Small Cell Lung Cancer Trial in Worldwide (Cosibelimab, Cisplatin, Carboplatin)

Active, not recruiting
  • Metastatic Non-squamous Non Small Cell Lung Cancer
  • Vitória, Brazil
  • +21 more
Aug 17, 2022

Lung Adenocarcinoma, Cryotherapy Effect Trial in Bordeaux (Cryoablation, Pembrolizumab, Pemetrexed)

Recruiting
  • Lung Adenocarcinoma
  • Cryotherapy Effect
  • Cryoablation
  • +3 more
  • Bordeaux, Gironde, France
    Institut Bergonié
Oct 29, 2021

Non-squamous Non-small-cell Lung Cancer, EGFR Activating Mutation Trial in Japan (Pembrolizumab, Lenvatinib, Carboplatin)

Recruiting
  • Non-squamous Non-small-cell Lung Cancer
  • EGFR Activating Mutation
  • Urayasu, Chiba, Japan
  • +9 more
Jul 19, 2022

NSCLC Trial in Japan, Korea, Republic of, Singapore (capmatinib, pemetrexed, cisplatin)

Terminated
  • Carcinoma, Non-Small-Cell Lung
  • Kashiwa, Chiba, Japan
  • +3 more
Jan 31, 2023

NSCLC Trial (Durvalumab, Tremelimumab, Pemetrexed)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • (no location specified)
Aug 17, 2023

Advanced Cancers Trial in Houston (Crizotinib (Xalkori), Pazopanib, Pemetrexed)

Terminated
  • Advanced Cancers
  • Crizotinib (Xalkori)
  • +2 more
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Sep 3, 2021

NSCLC Trial (PM8002, Placebo, Carboplatin)

Not yet recruiting
  • NSCLC
  • (no location specified)
Feb 23, 2023

Solid Tumor, Adult, Non-Hodgkin Lymphoma, Adult, NSCLC Trial in Rozzano, Siena, Glasgow (IOA-244, Avelumab Injection,

Recruiting
  • Solid Tumor, Adult
  • +4 more
  • Rozzano, Milan, Italy
  • +2 more
May 13, 2022

Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant, Infiltrating Bladder Urothelial Carcinoma With Glandular

Recruiting
  • Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
Nov 17, 2021

Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial in Tampa

Recruiting
  • Lung Non-Small Cell Carcinoma
  • +4 more
  • Tampa, Florida
    Moffitt Cancer Center
Aug 16, 2022

NSCLC Trial in China (Atezolizumab, Placebo, Bevacizumab)

Active, not recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Beijing City, China
  • +22 more
Dec 7, 2022

Stage II-IIIB(N2) NSCLC Trial in Shanghai (TQB2450, Carboplatin, Pemetrexed)

Not yet recruiting
  • Stage II-IIIB(N2) Non-small Cell Lung Cancer
  • Shanghai, Shanghai, China
    Shanghai Pulmonary Hospital
Oct 26, 2023

Lung Cancer, Non-squamous, Non-small Cell Trial (zongertinib, pembrolizumab, cisplatin)

Not yet recruiting
  • Lung Cancer, Non-squamous, Non-small Cell
  • (no location specified)
Nov 22, 2023

Mesothelioma, Malignant Trial in China (Nivolumab, Ipilimumab, Pemetrexed)

Recruiting
  • Mesothelioma, Malignant
  • Nivolumab
  • +4 more
  • Beijing, Beijing, China
  • +25 more
Jan 17, 2023

EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC Trial in Worldwide (Atezolizumab, Bevacizumab, Carboplatin)

Active, not recruiting
  • EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC
  • Großhansdorf, Germany
  • +17 more
Jan 12, 2023

NSCLC Trial in Seoul (Atezolizumab(Tecentriq), Pemetrexed, Bevacizumab)

Recruiting
  • Non-small Cell Lung Cancer
  • Seoul, Gangnamgu, Korea, Republic of
    Samsung Medical Center
Dec 27, 2021

Metastatic NSCLC, Stage III NSCLC Trial (inupadenant, Placebo, Carboplatin)

Recruiting
  • Metastatic NSCLC
  • Stage III NSCLC
  • Fayetteville, Arkansas
  • +16 more
Jan 25, 2023

Non Small Cell Lung Cancer, Advanced Lung Non-Small Cell Carcinoma, PD-L1 Gene Mutation Trial (Pembrolizumab, Pemetrexed,

Withdrawn
  • Non Small Cell Lung Cancer
  • +2 more
  • (no location specified)
Mar 14, 2022

Nonsquamous NSCLC Trial in Yichang (Sintilimab, Docetaxel, Pemetrexed)

Recruiting
  • Nonsquamous Non-Small Cell Lung Cancer
  • Yichang, Hubei, China
    Department of Medical Oncology, Central Hospital of Yichang City
Nov 5, 2021